Biological production of nicotinamide mononucleotide: a review.
Abstract
Nicotinamide mononucleotide (NMN) presents significant therapeutic potential against aging-related conditions, such as Alzheimer's disease, due to its consistent and strong pharmacological effects. Aside from its anti-aging effect, NMN is also an emerging noncanonical cofactor for orthogonal metabolic pathways in the field of biomanufacturing. This has significant advantages in the field of metabolic engineering, allowing cells to produce unnatural chemicals without disrupting the natural cellular processes. NMN is produced through both the chemical and biological methods, with the latter being more environmentally sustainable. The primary biological production pathway centers on the enzyme nicotinamide phosphoribosyltransferase, which transforms nicotinamide and phosphoribosyl pyrophosphate to NMN. Efforts to increase NMN production have been explored in microorganisms, such as:
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper discusses the biological production of nicotinamide mononucleotide (NMN), which has therapeutic potential against aging-related conditions, particularly Alzheimer's disease. While it touches on NMN's role in metabolic pathways and its production methods, it does not directly address the root causes of aging or lifespan extension. The focus on NMN's production and its applications in metabolic engineering suggests a solid contribution to the field, but the overall impact is limited as it primarily reviews existing knowledge rather than presenting novel findings or significant advancements.
Author of this paper? Send a correction.